SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is fueling a market rebound after a robust earnings report highlighted accelerating Azure growth and disciplined capital expenditure, easing long-standing investor concerns about AI infrastructure costs. Community sentiment is sharply divided between bullish traders betting on a sustained rally fueled by short-covering and cautious bears warning of potential profit-taking and technical resistance.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing heavy community debate as investors weigh strong operational execution, record-breaking ABS issuance, and insider buying against macro headwinds and short-seller volatility. While bulls point to the company's AI-driven platform and consistent earnings beats as evidence of massive upside, bears remain focused on interest rate sensitivity and the stock's challenging technical history.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing significant volatility as investors weigh disappointing earnings guidance and faster-than-expected revenue declines from Apple against long-term growth opportunities in AI and data centers. The community is actively debating the company's transition away from handset reliance, with some calling for patience as the business diversifies into automotive and IoT, while others remain critical of the recent margin pressures and downward analyst revisions.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense volatility as investors weigh persistent geopolitical tensions and rising Treasury yields against Microsofts resilient earnings and ongoing AI infrastructure spending. The community is actively debating whether recent price swings signal a fundamental market shift or a tactical opportunity for dip-buying amid broader concerns over interest rate policies and potential global economic instability.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing intense community discussion following a mixed securities shelf offering, which some investors fear signals upcoming dilution while others view it as a strategic move to provide financial flexibility for pipeline development. The conversation remains heavily focused on the anticipation of Phase 3 maintenance data and the potential for a partnership or buyout, as traders debate whether the stock's current volatility is a buying opportunity or a warning sign of further downside.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) is experiencing heightened volatility as investors grapple with a combination of persistent inflation concerns, rising crude oil prices due to geopolitical tensions in the Strait of Hormuz, and hawkish signals from Fed officials suggesting potential interest rate hikes. Community sentiment is deeply divided, with some investors betting on a long-term bottom for bonds amidst expectations of a structural economic breakdown, while others warn that higher yields and inflationary pressures will continue to pressure the fund's duration.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce is seeing strong momentum as investors weigh a series of positive catalysts, including major defense contract optimism, raised analyst price targets, and the company's leading role in the burgeoning small modular reactor (SMR) market. The community is actively discussing the firm's robust operational turnaround and its potential to capture significant market share in the rapidly expanding data center power and next-generation aviation sectors.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the UAE's marketing authorization of Anktiva for both bladder and lung cancer, a significant expansion of its global footprint that investors are betting will bolster upcoming earnings. Community sentiment remains polarized, with many longs pointing to this global expansion and strong sales commentary as evidence of a coming reversal, while others remain frustrated by persistent short interest and the lack of a major domestic partnership announcement.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing extreme volatility as investors weigh record-breaking earnings and strong AI-driven memory demand against concerns over semiconductor industry cycles and macroeconomic headwinds. The community is sharply divided, with bulls pointing to the company's long-term strategic importance in AI infrastructure while bears highlight recent capitulation patterns and potential risks from broader sector de-leveraging.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently experiencing high volatility as investors weigh strong long-term AI-driven compute demand against concerns over stretched valuations and recent analyst downgrades. The community is actively debating whether the stock's recent price swings represent a healthy consolidation for a long-term winner or a broader correction in the overheated semiconductor sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

eXoZymes says its platform can also produce cannabinoids, terpenes, and flavonoids. 
 
A May 2026 investor presentation from eXoZymes (Nasdaq: $EXOZ ) put the spotlight on the wider range of compounds its platform can make. Chairman Chris Marlett said cannabinoids are next in line, with terpenes and flavonoids behind them, and that the company is building its patents around the methods used to make these compounds. 
 
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 
 
Marlett traced the cannabinoid work back to the company’s earliest days: “So cannabinoids are next. Actually, ironically, it was the first thing we started to make. We started to make cannabinoids. We got grants to make it and we demonstrated that we could get yields.” 
 
The presentation also covered: 
• A platform the company says also extends to terpenes and flavonoids 
• A strategy to patent the methods used to make natural compounds, plus composition patents on engineered analogs and enzymes 
• A partnership model spanning contract manufacturers, supplement makers, and pharmaceutical companies 
• Recognition in scientific and news publications and grant funding the company cites as validation 
 
Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris 
 
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology. The company is building a pipeline of natural compounds and engineered analogs across nutraceutical and pharmaceutical applications. Learn more at https://exozymes.com. 
 
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. 
 
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. 
 
$DNLI, $TWST, $DNA, $ARKG

David Shapiro

top moon

Edward

Dwight

Ariana Storck

Bonnie Siegmund

Craig Salinas

Eugene Davenport

Michael Musto

Roberta Creech

Henry Callaghan

John Park

Melissa Vermillion

Shirley Hall

Micheal Fikes

Jeanne Hodges

James Adair

Kelly Distaffen

Nina Studdard

Renee Blankenship

Filomena Marsh

Raymond Oliver

Lucy Pena

Terry Skora

Amber Reilly

Edwina Packard

Karen Paris

Lillian Ellis

Ella Costello

Joseph Weiler

eXoZymes Inc. management brings together biotechnology and commercial expertise. The team combines scientific leadership from UCLA with business executives experienced in scaling technology companies, leveraging deep knowledge in enzyme engineering, artificial intelligence, and biomanufacturing to develop and commercialize cell-free production solutions for partners worldwide. The eXoZymes Inc.

B2idigital

eXoZymes Inc. | Nasdaq: EXOZ | B2i Digital Featured Company

eXoZymes' May 2026 investor presentation outlines the company's vision for transforming chemical manufacturing through AI-enhanced enzymes that operate outside living cells - exozymes - enabling scalable, sustainable, and highly efficient production of valuable molecules. The presentation...

TwentyThree

Investor Presentation by Chris Marlett (May 2026)

eXoZymes is redefining how complex molecules are discovered, manufactured, and commercialized. Its AI-enhanced, cell-free biomanufacturing platform turns rare, unscalable, or economically inaccessible chemistry into predictable, high-purity production. By embedding manufacturability directly into discovery, eXoZymes collapses development timelines, lowers capital intensity, and unlocks multiple commercialization paths.

Exozymes

Home - eXoZymes leading the next generation of biomanufacturing

b2i digital - connecting companies and investors through digital marketing, investor conferences, and direct introductions and meetings.

B2i Digital - Connecting companies and investors

Disclaimer - Content is provided "as is" by companies featured on the site. Conduct a trusted advisory before making investments.

Disclaimer - Consult an advisor before making any investments

StockTwits Web

eXoZymes Inc.

Denali Therapeutics Inc

Twist Bioscience Corp

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

ARK Investment Management LLC - ARK Genomic Revolution ETF

eXoZymes says its platform can also produce cannabinoids, terpenes, and flavonoids. 
 
A May 2026 investor presentation from eXoZymes (Nasdaq: 

 ) put the spotlight on the wider range of compounds its platform can make. Chairman Chris Marlett said cannabinoids are next in line, with terpenes and flavonoids behind them, and that the company is building its patents around the methods used to make these compounds. 
 
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at 

 
 
Marlett traced the cannabinoid work back to the company’s earliest days: “So cannabinoids are next. Actually, ironically, it was the first thing we started to make. We started to make cannabinoids. We got grants to make it and we demonstrated that we could get yields.” 
 
The presentation also covered: 
• A platform the company says also extends to terpenes and flavonoids 
• A strategy to patent the methods used to make natural compounds, plus composition patents on engineered analogs and enzymes 
• A partnership model spanning contract manufacturers, supplement makers, and pharmaceutical companies 
• Recognition in scientific and news publications and grant funding the company cites as validation 
 
Watch the full presentation: 

 
 
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology. The company is building a pipeline of natural compounds and engineered analogs across nutraceutical and pharmaceutical applications. Learn more at 

. 
 
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at 

. 
 
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of 

eXoZymes continues to expand the conversation around cell-free biomanufacturing with its work in cannabinoids, terpenes, and flavonoids. The company’s platform and patent strategy highlight how biotechnology could reshape the production of high-value natural compounds across nutraceutical and pharmaceutical markets. 
 
Learn more about B2i Digital Featured Company eXoZymes at: https://b2idigital.com/exozymes-1

eXoZymes continues to expand the conversation around cell-free biomanufacturing with its work in cannabinoids, terpenes, and flavonoids. The company’s platform and patent strategy highlight how biotechnology could reshape the production of high-value natural compounds across nutraceutical and pharmaceutical markets. 
 
Learn more about B2i Digital Featured Company eXoZymes at: 